Specialty Chemicals company Epigral announced Q2FY26 results Q2FY26 Financial Highlights: Plant utilization stood at 78% vs 73% in previous quarter Sales volume grew by 2% compared to previous quarter QoQ Revenue dropped by 4% to Rs 589 crore on account of drop in realizations in few of the products EBITDA margin stood at 23% vs 27% in Q1FY26 on account of drop in realizations and lower utilization PAT stood at Rs 51 crore H1FY26 Financial Highlights: Plant utilization stood at 75% vs 83% in H1FY25 Sales volume dropped in H1FY26 majorly on account of off season for few of the products and we expect sales volume to improve in H2FY26 Revenue dropped by 6% to Rs 1,204 crore on account of drop in sales volume EBITDA margin stood at 25% vs 28% in H1FY25 on account of drop in realizations and lower utilization Net Debt stood at Rs 496 crore vs Rs 489 crore as on 31st March 2025 ROCE stood at 21% and Net Debt/EBITDA stood at 0.8x Maulik Patel; Chairman and Managing Director – Epigral said: “This quarter ended with lower revenue on account of low sales volume and drop in realization of few products. Volume drop was majorly on account of extended monsoon which is off season for few products. Overall plant utilization stood at 75% for H1FY26 and we expect utilization to improve in H2FY26, as extended monsoon is over and maintenance work at plant is also completed, resulting in better H2 compared to H1. Our project to expand capacity of CPVC, Epichlorohydrin and Wind Solar Hybrid power plants are moving as per schedule and expected to be commissioned within committed timelines. These projects will drive growth from FY2027 onwards. We have further moved a step closer for the new projects. We will be announcing the same once it is freezed and approved by the board. We will continue to advance along our path of scalable profitable growth, optimize capital allocation, strengthen our integration, and create enduring value for all stakeholders.” Result PDF